The Efficacy and Safety of Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Update results of anlotinib plus TQB2450 presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2024 Results (n=18) assessing safety and efficacy of TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer presented at the 2024 Gastrointestinal Cancers Symposium
- 09 Sep 2023 Status changed from not yet recruiting to recruiting.